IDH1 and glioblastoma: To assess the specific effect of the vaccine on high grade glioma subgroups according to the newest brain tumor classification, we compared IDH-1 mutated cases form our series (today considered to be grade 4 astrocytomas, n = 9) with 23 patients in the GDC data bank; we also compared the patients in our group who had glioblastoma (n = 28) with 572 patients in the GDC with wild type IDH-1 (today considered glioblastoma).